|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:bioavailability
|
gptkb:unknown
|
|
gptkbp:chemical_formula
|
C40 H56 N6 O12 S
|
|
gptkbp:class
|
hormones
|
|
gptkbp:clinical_trial
|
completed
Phase 3
|
|
gptkbp:clinical_use
|
long-term treatment
|
|
gptkbp:contraindication
|
hypersensitivity to teduglutide
history of malignancy
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
gptkbp:drug_interactions
|
none known
|
|
gptkbp:effective_date
|
2012-08-30
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:frequency
|
once daily
|
|
gptkbp:healthcare
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gattex
|
|
gptkbp:indication
|
intestinal failure
|
|
gptkbp:ingredients
|
teduglutide
|
|
gptkbp:is_monitored_by
|
nutritional status
fluid balance
intestinal absorption
|
|
gptkbp:lifespan
|
approximately 13 hours
|
|
gptkbp:manufacturer
|
gptkb:NPS_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
GLP-2 analog
|
|
gptkbp:metabolism
|
proteolytic cleavage
|
|
gptkbp:packaging
|
single-use vial
|
|
gptkbp:patient_education
|
dietary recommendations
injection technique
side effects awareness
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:price
|
varies by pharmacy
|
|
gptkbp:provides_guidance_on
|
recommended
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research
|
ongoing
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
headache
nausea
abdominal pain
infections
injection site reactions
gastrointestinal disorders
neoplasms
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:trade
|
gptkb:Gattex
|
|
gptkbp:used_for
|
short bowel syndrome
|
|
gptkbp:weight
|
873.01 g/mol
|
|
gptkbp:bfsParent
|
gptkb:NPS_Corporation
gptkb:NPS_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|